Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB145 Safety and PK Study in Healthy Adults
NCT07225517Phase 1Recruiting
- Sponsor
- Biogen
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB145 in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events at 28 days, Number of Participants With Clinical Laboratory Abnormalities at 28 days and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
BIIB145
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07225517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225517.